Eicosapentaenoic Acid
Omega-3 Fatty Acids
Icosapent ethyl ‘could have relevance’ for lowering CV risk in adults with CAD on statins
Icosapent ethyl significantly reduced coronary events and led to numerically fewer CV events at 5 years for patients with CAD and low plasma eicosapentaenoic acid already taking statin therapy, researchers reported.
Eicosapentaenoic acid appears to counteract harmful CV effects from air pollution
Eicosapentaenoic acid, the active ingredient in certain omega-3 fatty acids, promoted anti-inflammatory, cytoprotective and lipid changes in endothelial cells exposed to air pollution, researchers reported.
RESPECT-EPA
Highly purified eicosapentaenoic acid vs. usual care in Japanese adults with chronic CAD receiving statins.
‘Possible’ benefit with highly purified EPA to reduce CV risk in CAD with statin therapy
CHICAGO — In Japanese adults with chronic CAD already treated with statin therapy, highly purified eicosapentaenoic acid showed borderline statistical significance in reducing risk for adverse CV events, researchers reported.
Top in cardiology: EPA monotherapy, ambulatory BP
A new meta-analysis discussed how eicosapentaenoic acid monotherapy, compared with eicosapentaenoic acid plus docosahexaenoic acid, provided the greatest reduction in cardiovascular risk.
In omega-3 fatty acid trials, EPA alone yields greater CV risk reduction vs. EPA plus DHA
In a meta-analysis of omega-3 fatty acid trials, eicosapentaenoic acid monotherapy yielded the greatest reduction in CV risk vs. a combination of eicosapentaenoic acid and docosahexaenoic acid.
In high-risk patients taking icosapent ethyl, EPA levels linked to HF rates
In patients from the REDUCE-IT trial assigned icosapent ethyl, those who achieved high or moderate levels of eicosapentaenoic acid had better HF outcomes compared with those who achieved low levels, researchers reported.
Top in cardiology: Highlights from the American College of Cardiology Scientific Session
The American College of Cardiology recently held its annual meeting. Healio’s coverage of the virtual conference made up the top stories in cardiology last week.
Higher DHA levels reduce protective impact of EPA on major adverse CV events
Higher levels of eicosapentaenoic acid were associated with reductions in major adverse events, in particular improved survival, according to a presentation at the American College of Cardiology Scientific Session.